Patterson is looking for answers to diagnose and treat several phases of this pandemic. I think he grasps and appreciates both the economic and human elements involved. He's done the grunt work to brute force analyze blood samples from (I'm guessing) hundreds of the affected and I have little doubt he's gleaned real insights that will aid in those objectives. It's not wrong of him to harvest the fruits of that labor with respect to long haulers, imo, as LH isn't a terminal diagnosis.

His collaboration with CytoDyn and CCR5 RO could have easily been motivation to proselytize LLMab... That never occurred to anyone? Just as realization that may not be the most lucrative market for him or his company may have been the reason he shifted focus?

Everyone has an angle. LLMab still binds to CCR5, has no know adverse events associated, has a longer half life... Nothing Patterson or Feuerstein, or anyone else can say can change that.